Sign in

APLM on Nasdaq

Apollomics Inc.

Pharmaceutical preparations company based in Foster City, Cayman Islands1

In its 2026 annual report (Form 20-F) the company says: “Apollomics is a holding company incorporated in the Cayman Islands. Our primary business is conducted at our U.S. headquarters with our global drug development team located in the San Francisco Bay Area. We also operate in China with our discovery and development team located in Hangzhou.”4 Its shares trade on Nasdaq under the symbol APLM.1

$21.10 down 0.67 (3.08%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerAPLM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCovina, California1
  • Incorporated inCayman Islands3
  • Business address668 Arrow Grand Cir, Suite 206, Covina, Ca 917723
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We were originally formed as CB Therapeutics Inc. as a result of a spin-off of Crown Bioscience International, which was completed on December 31, 2015. As a result, we became the owner of certain patent and intellectual property rights relating to some of our product candidates. Since our founding, we have built a pipeline focused on oncology, of which three product candidates remain in active clinical stage development. For more information relating to the series of transactions resulting in our acquisition of these patent rights, please see “ —Intellectual Property Assignment ”, below.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-1107.3%Return on equity5
-$28.8MFree cash flow5

Financial statements

Revenue675$0 in 2024
02020: $0$020202021: $0$020212022: $0$020222023: $0$020232024: $0$02024
Net income675-$53.9M in 2024−28% since 2020
-$300.0M-$200.0M-$100.0M02020: -$74.8M-$74.8M20202021: -$94.8M-$94.8M2021+27%2022: -$240.8M-$240.8M2022+154%2023: -$172.6M-$172.6M2023−28%2024: -$53.9M-$53.9M2024−69%

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Revenue$8.5M
Other income$494.0K$1.5M$1.2M
Foreign exchange (losses) gains-$141.0K$145.0K$1.2M
Fair value change of financial assets at FVTPL$198.0K$821.0K
Fair value change of financial liabilities at FVTPL-$22.0K$222.0K$1.6M
Fair value change of convertible preferred shares$0$0-$76.4M
Research and development expenses-$5.5M-$24.6M-$34.2M
Administrative expenses-$12.4M-$17.8M-$20.6M
Impairment of intangible assets-$1.7M-$13.0M$0
Finance costs-$65.0K-$179.0K-$150.0K
Other expense-$12.0K-$140.0K-$46.0M
Loss before taxation-$10.9M-$53.6M-$172.6M
Income tax expenses-$3.0K-$259.0K-$10.0K
Loss and total comprehensive loss for the period, net of taxation, attributable to owners of the Company-$10.9M-$53.9M-$172.6M
Basic loss per common share (US$)-$7.57-$52.80-$231.99
Diluted loss per common share (US$)-$7.57-$52.80-$231.99

Compare Apollomics Inc. with another company

Corporate structure

Apollomics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Apollomics Inc.

  • Hung-Wen Chen Filed SCHEDULE 13D/A on Apollomics Inc., latest Aug 17, 2026 (4 filings since May 20, 2024)
  • Yi-Kuei Chen Filed SCHEDULE 13D/A on Apollomics Inc., latest Aug 14, 2026 (2 filings since Apr 8, 2026)
  • Maxpro Investment Co., Ltd Filed SCHEDULE 13G/A on Apollomics Inc., latest Sep 5, 2025 (3 filings since May 20, 2024)
  • Alpha Intelligence Enterprises Ltd. Filed SCHEDULE 13G/A on Apollomics Inc., latest Jan 10, 2025 (2 filings since Feb 27, 2024)
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Apollomics Inc., latest Aug 15, 2024 (7 filings since Apr 12, 2023)
  • Guo-Liang Yu Filed SC 13D on Apollomics Inc., latest Oct 10, 2023
  • Apollomics Inc. Covina, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Apollomics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$92.0K5 Dec 31, 2024$161.0K5 Dec 31, 2023−42.9%
Operating-lease assets (leased space)$927.0K5 Dec 31, 2024$425.0K5 Dec 31, 2023+118.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$9.8M5 Dec 31, 2024$32.1M5 Dec 31, 2023−69.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.7M5 Dec 31, 2024$14.8M5 Dec 31, 2023−88.2%

Leadership

Who has led Apollomics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Hung-Wen Chen2026–now

Chief financial officer

  1. Peter Kuan-How Lin2026–now
Board members and other officers (7)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorYi-Kuei (Alex) Chen named Aug 19, 202617
  • DirectorHong-Jung (Moses) Chen named Aug 19, 202617

Timeline

  1. Mar 19, 2026New chief executive Hung-Wen Chen becomes CEO9

Filings

183 filings to the SEC since October 2021: 5 annual reports, 40 insider forms, 19 large holders, 1 private raises, 118 other. The latest 20:

  1. Sep 24, 20264/A EDGAR
  2. Sep 24, 20264/A EDGAR
  3. Sep 24, 20264/A EDGAR
  4. Sep 17, 20264 EDGAR
  5. Sep 17, 20264 EDGAR
  6. Sep 17, 20264 EDGAR
  7. Sep 17, 20264 EDGAR
  8. Sep 17, 20264 EDGAR
  9. Sep 17, 20264 EDGAR
  10. Sep 17, 20264 EDGAR
  11. Sep 8, 2026424B3 EDGAR
  12. Aug 24, 20264 EDGAR
  13. Aug 19, 2026D EDGAR
  14. Aug 17, 20264 EDGAR
  15. Aug 17, 20264 EDGAR
  16. Aug 17, 20264 EDGAR
  17. Aug 17, 2026SCHEDULE 13D/A EDGAR
  18. Aug 14, 2026SCHEDULE 13D/A EDGAR
  19. Aug 12, 20266-K EDGAR
  20. Jul 24, 20263 EDGAR

The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 14, 2026Chen Yi-KueiChief Operating OfficerBuy20,000$15.00$300.0KForm 4
Aug 14, 2026LIN PETER KUAN-HOWChief Financial OfficerBuy26,667$15.00$400.0KForm 4
Aug 14, 2026Chen Hung-WenChief Executive OfficerBuy536,667$14.07$7.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$10.0M 2026–2026
Money received by yearMoney received by year, 2026–2026: $10.0M in all. Private raises (Form D) $10.0M.$0$2.5M$5M$7.5M$10M2026 · Private raises (Form D): $10.0M2026
Figures by year
YearPrivate raises (Form D)Total
2026$10.0M$10.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Aug 14, 2026Raised $10 million in a private offering of equity17 Form D: 8 investors so far Form D

SEC filer profile

How Apollomics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARApollomics Inc.1
  • CIK0001944885
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address668 Arrow Grand Cir, Suite 206, Covina, CA 917721
  • Phone1-650-209-40551
  • Shares outstanding2,196,052 shares as of Apr 24, 20264
  • AuditorMarcum Asia CPAs LLP, New York, New York PCAOB ID 5395; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 14, 20221
  • Filings183 in all: 6-K (38), 4 (20), CORRESP (15), 424B3 (12), UPLOAD (11), 3 (9), 3/A (8), 425 (8)1
    All 33 form types

    EFFECT (7), SC 13D/A (6), 20-F (5), 144 (4), F-3 (4), F-4/A (4), 4/A (3), F-3/A (3), SC 13G (3), SCHEDULE 13D/A (3), S-8 (2), SC 13D (2), SCHEDULE 13D (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 424B5 (1), 8-A12B (1), CERT (1), D (1), DRS (1), F-1 (1), F-1/A (1), F-4 (1), POS AM (1), SC 13G/A (1)

  • Latest filingsAnnual report (20-F) Apr 24, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary Shares, par value $0.01 per shareAPLMThe Nasdaq Stock Market LLC
Warrants, each exercisable to purchase one Class A Ordinary Share at an exercise price of $11.50 per 0.01 shareAPLMWThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Apr 24, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
    Yahoo FinanceAPLM quote
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23